Featured
July 16, 2020 by Joseph Morton
War is a part of human nature. It’s the greatest driver of human innovation, and if we’re inclined to be cynical we could state that it’s the key reason our civilization is advanced as it is. If it weren’t for the catalyst of hundreds of years of continuous war, including the prospect of mutually assured […] June 26, 2020 by Joseph Morton
One of Roadman Investments (LITT.V) subsidiaries, CLOV Biopharma, recently completed its research program at UBC on cedar leaf oil vapour, but the Securities Exchange Commission (SEC) doesn’t care. The research program has taken a bit longer than the company would have liked, courtesy of COVID-19, but the company’s doctors have acquired most of the exemptions […] June 18, 2020 by Chris Parry
The big knock on shroom companies in the public markets right now is that most of them are chancers rather than pioneers – markets guys looking to acquire any asset that could convince a psychedelics investor to toss coin at their stock. The track record of EGF Theramed (aka Theramed, aka Evatrade Health, aka […] Latest
December 24, 2020 by Joseph Morton
The notion of magic mushroom market offering after the legalization of cannabis has been floated time and again since long before cannabis legalization was even on the table. It would be late night at parties among my older friends who after they finished their mandatory rant on how cannabis should be legalized and regulated and […] December 17, 2020 by Joseph Morton
Numinus Wellness (NUMI.V) finished their first legal extraction of psilocybe mushrooms in Canada for research purposes today, according to a press release. This follows the company’s completion of their first cultivation and harvest of psilocybe mushrooms at their 7,000 square foot analytics and research laboratory. “Completing the first legal extraction of Psilocybe mushrooms in Canada […] December 9, 2020 by Joseph Morton
Red Light Holland (TRIP.C) is up 17.1% on the day, culminating in a blast-off trend that’s seen them rise from last month’s high of $.07 to now trade at $0.205. It’s been an interesting month for the nascent psilocybin market, which has benefited from greater visibility and shifting regulatory sands and opened options for United […] November 10, 2020 by Joseph Morton
A few states in our neighbour to the south decided to offer psilocybin based therapies during the most recent spate of elections, prompting more potential for companies like Xphyto Therapeutics (XPHY.C) to get on top of a burgeoning market. This comes at the behest of the U.S. Food and Drug Administration’s two recent designations for […]
